Literature DB >> 27649657

miRNA-21 sensitizes gastrointestinal stromal tumors (GISTs) cells to Imatinib via targeting B-cell lymphoma 2 (Bcl-2).

C-L Cao1, H-J Niu, S-P Kang, C-L Cong, S-R Kang.   

Abstract

OBJECTIVE: miRNA-21 (miRNA-21) has recently been recognized to tumor suppressive in various types of cancers. However, the role of miRNA-21 in gastrointestinal stromal tumors (GISTs) is still ambiguous. In this study, we investigated the regulation by miRNA-21 on the sensitivity of gastrointestinal stromal tumors (GISTs) cells to Imatinib.
MATERIALS AND METHODS: We examined the expression of miRNA-21 and B-cell lymphoma 2 (Bcl-2) in GIST specimens by the real-time quantitative PCR assay (RT-qPCR). Then we explored the regulation by miRNA-21 on the Bcl-2 expression by the RT-qPCR assay, Western blotting assay and the luciferase assay in GIST-T1 cells. In addition, we examined the influence of miRNA-21 on the sensitivity to Imatinib of GIST-T1 cells with colony forming assay and apoptotic assay.
RESULTS: Results indicated that miRNA-21 expression was suppressed in GIST tissues. And we identified putative miRNA-21 binding sites within the 3'-untranslated region (3'-UTR) of the human Bcl-2 gene. Transient transfection of miRNA-21 mimics into human GIST GIST-T1 cell line significantly downregulated the Bcl-2 expression in both mRNA and protein levels. Moreover, the miRNA-21 mimics transfection markedly aggravated the Imatinib-mediated growth inhibition and apoptosis induction in GIST-T1 cells.
CONCLUSIONS: Our results demonstrated that miRNA-21 suppressed Bcl-2 expression in GIST cells and could function as a potent tumor suppressor in GIST. And the miRNA-21 promotion could sensitize GIST cells to Imatinib. It implies a potential role in the GIST treatment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27649657

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

Review 1.  The Network of Non-coding RNAs in Cancer Drug Resistance.

Authors:  Fabio Corrà; Chiara Agnoletto; Linda Minotti; Federica Baldassari; Stefano Volinia
Journal:  Front Oncol       Date:  2018-08-29       Impact factor: 6.244

Review 2.  Noncoding RNAs in Drug Resistance of Gastrointestinal Stromal Tumor.

Authors:  Jiehan Li; Shuning Guo; Zhenqiang Sun; Yang Fu
Journal:  Front Cell Dev Biol       Date:  2022-01-31

3.  Knockdown of lncRNA BDNF-AS inhibited the progression of multiple myeloma by targeting the miR-125a/b-5p-BCL2 axis.

Authors:  Min Chu; Yingchao Fan; Liting Wu; Xiaoyan Ma; Jinfeng Sao; Yonghua Yao; Wenfang Zhuang; Cui Zhang
Journal:  Immun Ageing       Date:  2022-01-03       Impact factor: 6.400

Review 4.  Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistance.

Authors:  Alfred Buhagiar; Elisa Seria; Miriana Borg; Joseph Borg; Duncan Ayers
Journal:  Cancer Drug Resist       Date:  2021-10-26

Review 5.  Small Molecules in Rare Tumors: Emerging Role of MicroRNAs in GIST.

Authors:  Juozas Kupcinskas
Journal:  Int J Mol Sci       Date:  2018-01-30       Impact factor: 5.923

6.  MiR-374b Promotes Proliferation and Inhibits Apoptosis of Human GIST Cells by Inhibiting PTEN through Activation of the PI3K/Akt Pathway.

Authors:  Zi-Wen Long; Jiang-Hong Wu; Ya-Nong Wang; Ye Zhou
Journal:  Mol Cells       Date:  2018-06-14       Impact factor: 5.034

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.